Molecular targets in the inhibition of angiogenesis

Arkadiusz Z Dudek, Wojciethc Z. Pawlak, Mark N. Kirstein Pharm

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Angiogenesis, the process of blood vessel formation, is crucial for malignant tumour growth and metastases; therefore, it has become an attractive target for anticancer therapy. Theoretically applicable to most solid tumours, this therapy may be advantageous over existing cytotoxic therapy, since it is directed at genetically stable endothelium growing within tumours rather than at malignant cells, which acquire resistance to treatment. Many promising angiogenesis inhibitors have been developed, although their activity has yet to be demonstrated in human clinical trials. To improve therapeutic benefit, this may require further insight into tumour angiogenesis, development of appropriate surrogate markers of activity, treatment of early stage neoplastic disease and probably a combination of different classes of antiangiogenesis agents to overcome redundant mechanisms of angiogenesis control.

Original languageEnglish (US)
Pages (from-to)527-541
Number of pages15
JournalExpert Opinion on Therapeutic Targets
Issue number4
StatePublished - Aug 1 2003


  • Antiangiogenic therapy
  • Tumour angiogenesis
  • Vascular endothelial growth factor (VEGF)


Dive into the research topics of 'Molecular targets in the inhibition of angiogenesis'. Together they form a unique fingerprint.

Cite this